Advertisement
Research Article Free access | 10.1172/JCI112318
Find articles by Nesheim, M. in: JCI | PubMed | Google Scholar
Find articles by Nichols, W. in: JCI | PubMed | Google Scholar
Find articles by Cole, T. in: JCI | PubMed | Google Scholar
Find articles by Houston, J. in: JCI | PubMed | Google Scholar
Find articles by Schenk, R. in: JCI | PubMed | Google Scholar
Find articles by Mann, K. in: JCI | PubMed | Google Scholar
Find articles by Bowie, E. in: JCI | PubMed | Google Scholar
Published February 1, 1986 - More info
A coagulation Factor V inhibitor developed in a man 75 yr of age in association with an anaplastic malignancy and drug treatment (including the aminoglycoside antibiotic, gentamicin). The patient did not bleed abnormally, despite both surgical challenge and plasma Factor V activity of less than 1%. The inhibited plasma had grossly prolonged prothrombin and activated partial thromboplastin times, but a normal thrombin time. Mixing studies indicated progressive coagulation inhibition with normal plasma, but not with Factor V-deficient plasma, and reversal of coagulation inhibition by the addition of bovine Factor V to the patient's plasma. 1 ml of patient plasma inhibited the Factor V activity of 90 ml of normal human plasma. The inhibitor was isolated by sequential affinity chromatography on protein A-Sepharose and Factor V-Sepharose. The IgG isolate markedly inhibits the activity of prothrombinase assembled from purified Factors Xa and Va, calcium ion, and phospholipid vesicles, and partially inhibits prothrombinase assembled from purified Factor Xa, calcium ion, and normal platelets. The Factor V of platelets, however, appears relatively inaccessible to the antibody, inasmuch as platelets isolated from whole blood supplemented for 8 h with the antibody functioned normally with respect to platelet Factor V-mediated prothrombinase function. The absence of obvious hemorrhagic difficulties in the patient, the total inhibition of plasma Factor V by the inhibitor, and the apparent inaccessibility of platelet Factor V to the inhibitor specifically implicate platelet Factor V in the maintenance of hemostasis.
Images.